A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo

To the Editor: Current treatments for vitiligo are limited in efficacy, often producing suboptimal results. Recent studies have established that CD8+  T-cell and interferon γ signaling, mediated by the Janus kinase (JAK)–signal transducer and activator of transcription pathway, contribute to the pathogenesis of vitiligo.1 JAK inhibitors block this pathway and are currently Food and Drug Administration approved for autoimmune diseases, includi ng psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and myeloproliferative disorders.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: Research letter Source Type: research